Curevac provides update on trial dates for patent litigation across multiple geographies against pfizer/biontech

New trial date for u.s. patent litigation set for march 3, 2025, following settlement with acuitas therapeutics first instance decision on validity of ep 3 708 668 b1 (split poly-a tail technology) scheduled for march 25, 2025, by european patent office in the context of the german patent litigation uk trial on validity of intellectual property rights ep 3 708 668 b1 and ep 4 023 755 b1 (split poly-a tail technology) began july 10; judgement expected later in 2024 tÜbingen, germany and boston, ma / accesswire / july 11, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced the latest trial dates for its ongoing patent litigation against pfizer/biontech in multiple geographies including the u.s., uk and germany.
CVAC Ratings Summary
CVAC Quant Ranking